Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Children and teenagers between 1 and 18 years old, of any gender.
• People newly diagnosed with classical Hodgkin lymphoma (a type of blood cancer) confirmed by a tissue test, who fall into either a "low-risk" group (early-stage disease without large tumours) or an "intermediate-risk" group (slightly more advanced or symptomatic disease, with or without large tumours).
• People who have at least one measurable area of disease that can be tracked during the trial.
• Male participants with the ability to father children who agree not to donate sperm and to use contraception or abstinence throughout the treatment period.
• Female participants who are not pregnant or breastfeeding, and who either cannot become pregnant or agree to use approved contraception for at least 120 days after the last treatment dose, and agree not to donate or store eggs during that time.
• People with a general health and activity score of at least 50 out of 100 on the appropriate scale for their age (Lansky scale for those under 16, Karnofsky scale for those 16 and older).
• People whose blood test results during screening meet certain minimum standards for blood cell counts, liver function, and kidney function (confirm with trial site for exact values).
• People who are able to attend outpatient visits, laboratory check-ups, and other required appointments throughout the study.
• People whose parents or legal guardians are able to understand and sign the consent forms before any study procedures begin, and where appropriate, the participant themselves is also able to give their agreement.

Who may not be able to join:

• People who have had a solid organ transplant at any point, or a bone marrow/stem cell transplant from a donor within the past 5 years.
• Female participants who test positive on a pregnancy test within 24 hours before the first dose.
• People whose heart is not pumping efficiently enough, based on specific heart function measurements below set thresholds (confirm with trial site for exact values).
• People who have previously been treated with certain immunotherapy drugs that target the PD-1, PD-L1, or PD-L2 pathways, or similar drugs that affect the immune system in this way.
• People who have already received any systemic cancer treatment for their current diagnosis before joining the study.
• People who have received a live or weakened (attenuated) vaccine within the 30 days before the first study treatment.
• People who have taken part in another drug or device trial within the 4 weeks before the study treatment starts.
• People diagnosed with a specific subtype called lymphocyte-predominant Hodgkin lymphoma (a different form of the disease).
• People with a known immune deficiency, or who have been taking long-term steroid or other immune-suppressing medicines within 7 days before the first dose.
• People who have had another active cancer requiring treatment within the past 3 years.
• People whose cancer has spread to the brain or spinal fluid, as detected on imaging at the time of diagnosis.
• People with a history of severe allergic reactions (grade 3 or higher) to any of the study treatments or their ingredients.
• People with an active autoimmune disease (where the immune system attacks the body) that has required treatment within the past 2 years.
• People with a history of serious lung inflammation (pneumonitis or interstitial lung disease) that required steroid treatment, or who currently have an active lung infection requiring treatment.
• People with a known HIV infection.
• People with a known history of hepatitis B, or an active hepatitis C infection.
• People with any other condition, treatment, or abnormal test result that the treating doctor believes could interfere with the study or would not be in the person's best interest.
• People with a known mental health condition or substance use disorder that could make it difficult to follow the study requirements.
• People who have not fully recovered from a major surgical procedure, or who still have ongoing complications from surgery.
• People excluded for other reasons at the discretion of the trial investigator.

Important: Always verify eligibility with the trial site directly before applying.